AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
RETROSPECTIVE ANALYSIS OF INFECTIOUS-DISEASE IN PATIENTS WHO RECEIVEDRECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR VERSUS PATIENTS NOT RECEIVING A CYTOKINE WHO UNDERWENT AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR TREATMENT OF LYMPHOID CANCER
Authors: NEMUNAITIS J BUCKNER CD DORSEY KS WILLIS D MEYER W APPELBAUM F
Citation: J. Nemunaitis et al., RETROSPECTIVE ANALYSIS OF INFECTIOUS-DISEASE IN PATIENTS WHO RECEIVEDRECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR VERSUS PATIENTS NOT RECEIVING A CYTOKINE WHO UNDERWENT AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR TREATMENT OF LYMPHOID CANCER, American journal of clinical oncology, 21(4), 1998, pp. 341-346
REPRODUCIBILITY IN RETROSPECTIVE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC MARROW TRANSPLANTATION
Authors: MARTIN P NASH R SANDERS J LEISENRING W ANASETTI C DEEG HJ STORB R APPELBAUM F
Citation: P. Martin et al., REPRODUCIBILITY IN RETROSPECTIVE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC MARROW TRANSPLANTATION, Bone marrow transplantation, 21(3), 1998, pp. 273-279
ISOLATION OF CD34(-CELL COMPONENTS USING THE BAXTER ISOLEX SYSTEM() CELLS FROM BLOOD STEM)
Authors: ROWLEY SD LOKEN M RADICH J KUNKLE LA MILLS BJ GOOLEY T HOLMBERG L MCSWEENEY P BEACH K MACLEOD B APPELBAUM F BENSINGER WI
Citation: Sd. Rowley et al., ISOLATION OF CD34(-CELL COMPONENTS USING THE BAXTER ISOLEX SYSTEM() CELLS FROM BLOOD STEM), Bone marrow transplantation, 21(12), 1998, pp. 1253-1262
BONE-MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID-LEUKEMIA
Authors: HANSEN JA GOOLEY TA MARTIN PJ APPELBAUM F CHAUNCEY TR CLIFT RA PETERSDORF EW RADICH J SANDERS JE STORB RF SULLIVAN KM ANASETTI C
Citation: Ja. Hansen et al., BONE-MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID-LEUKEMIA, The New England journal of medicine, 338(14), 1998, pp. 962-968
METHODS FOR ASSESSMENT OF GRAFT-VERSUS-HOST DISEASE
Authors: MARTIN PJ SCHOCH G GOOLEY T ANASETTI C DEEG HJ NASH R SANDERS J STORB R APPELBAUM F
Citation: Pj. Martin et al., METHODS FOR ASSESSMENT OF GRAFT-VERSUS-HOST DISEASE, Blood, 92(9), 1998, pp. 3479-3480
USE OF INTERFERON-ALPHA-2A TO TREAT CYTOGENETIC RELAPSE OF CHRONIC MYELOID-LEUKEMIA AFTER MARROW TRANSPLANTATION
Authors: HIGANO CS CHIELENS D RASKIND W BRYANT E FLOWERS MED RADICH J CLIFT R APPELBAUM F
Citation: Cs. Higano et al., USE OF INTERFERON-ALPHA-2A TO TREAT CYTOGENETIC RELAPSE OF CHRONIC MYELOID-LEUKEMIA AFTER MARROW TRANSPLANTATION, Blood, 90(7), 1997, pp. 2549-2554
CELL-CYCLE ARREST AND THERAPEUTIC SENSITIVITY IN DE-NOVO AML
Authors: BANKER D WILLMAN C GROUDINE M APPELBAUM F
Citation: D. Banker et al., CELL-CYCLE ARREST AND THERAPEUTIC SENSITIVITY IN DE-NOVO AML, Blood, 90(10), 1997, pp. 290-290
CONVERSION TO FK506 FOR CYCLOSPORINE (CSP)-RESISTANT ACUTE GVHD OR CSP-ASSOCIATED TOXICITY
Authors: FURLONG T STORB R ANASETTI C APPELBAUM F DEEG HJ DONEY K MARTIN P SULLIVAN KM WITHERSPOON R NASH RA
Citation: T. Furlong et al., CONVERSION TO FK506 FOR CYCLOSPORINE (CSP)-RESISTANT ACUTE GVHD OR CSP-ASSOCIATED TOXICITY, Blood, 90(10), 1997, pp. 458-458
SAFETY AND ACTIVITY OF RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IN PATIENTS (PTS) WITH DELAYED PLATELET RECOVERY (DPR)
Authors: NASH R KURZROCK R DIPERSIO J NIMER S VOSE J MAHARAJ D LINKER C NADEMANEE A NEGRIN R ASHBY M TREMBLAY T JONES D APPELBAUM F CHAMPLIN R
Citation: R. Nash et al., SAFETY AND ACTIVITY OF RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IN PATIENTS (PTS) WITH DELAYED PLATELET RECOVERY (DPR), Blood, 90(10), 1997, pp. 1151-1151
HIGH-DOSE BUSULFAN, MELPHALAN AND THIOTEPA (BUMELTT) FOLLOWED BY AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELLS (PBSC) RESCUE IN PATIENTS WITH ADVANCED-STAGE III IV OVARIAN-CANCER/
Authors: HOLMBERG LA DEMIRER T SCIFFMAN K ROWLEY SD BUCKNER CD GOODMAN G MAZIARZ R APPELBAUM F BENSINGER WI
Citation: La. Holmberg et al., HIGH-DOSE BUSULFAN, MELPHALAN AND THIOTEPA (BUMELTT) FOLLOWED BY AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELLS (PBSC) RESCUE IN PATIENTS WITH ADVANCED-STAGE III IV OVARIAN-CANCER/, Blood, 90(10), 1997, pp. 1705-1705
MARROW TRANSPLANTATION FOR FANCONI-ANEMIA - CONDITIONING WITH REDUCEDDOSES OF CYCLOPHOSPHAMIDE WITHOUT RADIATION
Authors: FLOWERS MED ZANIS J PASQUINI R DEEG HJ RIBEIRO R LONGTON G MEDEIROS CR DONEY K SANDERS J BRYANT E HANSEN J SULLIVAN KM APPELBAUM F THOMAS ED STORB R
Citation: Med. Flowers et al., MARROW TRANSPLANTATION FOR FANCONI-ANEMIA - CONDITIONING WITH REDUCEDDOSES OF CYCLOPHOSPHAMIDE WITHOUT RADIATION, British Journal of Haematology, 92(3), 1996, pp. 699-706
INCIDENCE OF PERIPHERAL NEUROPATHY (PN) PRIOR TO THALIDOMIDE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD)
Authors: FLOWERS MED TAPSCOTT SJ EMERSON J EMERSON MV REAGAN T TAYLOR L AJER T SIADAK M SANDERS J ZWINGENBERGER K WILLSMANN K APPELBAUM F SULLIVAN KM
Citation: Med. Flowers et al., INCIDENCE OF PERIPHERAL NEUROPATHY (PN) PRIOR TO THALIDOMIDE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD), Blood, 88(10), 1996, pp. 2423-2423
RANDOMIZED COMPARISON OF PENTOSTATIN VERSUS INTERFERON ALFA-2A IN PREVIOUSLY UNTREATED PATIENTS WITH HAIRY-CELL LEUKEMIA - AN INTERGROUP STUDY
Authors: GREVER M KOPECKY K FOUCAR MK HEAD D BENNETT JM HUTCHISON RE CORBETT WEN CASSILETH PA HABERMANN T GOLOMB H RAI K EISENHAUER E APPELBAUM F CHESON BD
Citation: M. Grever et al., RANDOMIZED COMPARISON OF PENTOSTATIN VERSUS INTERFERON ALFA-2A IN PREVIOUSLY UNTREATED PATIENTS WITH HAIRY-CELL LEUKEMIA - AN INTERGROUP STUDY, Journal of clinical oncology, 13(4), 1995, pp. 974-982
FACTORS THAT INFLUENCE COLLECTION AND ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELLS
Authors: BENSINGER W APPELBAUM F ROWLEY S STORB R SANDERS J LILLEBY K GOOLEY T DEMIRER T SCHIFFMAN K WEAVER C CLIFT R CHAUNCEY T KLARNET J MONTGOMERY P PETERSDORF S WEIDEN P WITHERSPOON R BUCKNER CD
Citation: W. Bensinger et al., FACTORS THAT INFLUENCE COLLECTION AND ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELLS, Journal of clinical oncology, 13(10), 1995, pp. 2547-2555
OPTIMAL TREATMENT FOR UNTREATED PATIENTS WITH HAIRY-CELL LEUKEMIA - REPLY
Authors: GREVER M KOPECKY K APPELBAUM F FOUCAR MK
Citation: M. Grever et al., OPTIMAL TREATMENT FOR UNTREATED PATIENTS WITH HAIRY-CELL LEUKEMIA - REPLY, Journal of clinical oncology, 13(10), 1995, pp. 2678-2679
PHASE-III RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RHGM-CSF FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: NEMUNAITIS J ROSENFELD CS ASH R FREEDMAN MH DEEG HJ APPELBAUM F SINGER JW FLOMENBERG N DALTON W ELFENBEIN GJ RIFKIN R RUBIN A AGOSTI J HAYES FA HOLCENBERG J SHADDUCK RK
Citation: J. Nemunaitis et al., PHASE-III RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RHGM-CSF FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION, Bone marrow transplantation, 15(6), 1995, pp. 949-954
PUVA AS ADJUVANT PRIMARY OR SALVAGE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD)
Authors: THOMPSON D SULLIVAN K SEIDEL K ERICKSON K FLOWERS M SIADAK M APPELBAUM F OLERUD J STORB R
Citation: D. Thompson et al., PUVA AS ADJUVANT PRIMARY OR SALVAGE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD), Journal of investigative dermatology, 104(4), 1995, pp. 659-659
RETROSPECTIVE ANALYSIS OF INFECTIOUS-DISEASE IN PATIENTS WHO RECEIVEDLEUKINE VERSUS PATIENTS NOT RECEIVING A CYTOKINE WHO UNDERWENT AUTOLOGOUS BONE-MARROW TRANSPLANT (ABMT) FOR TREATMENT OF LYMPHOID CANCER
Authors: NEMUNAITIS J BUCKNER CD DORSEY KS WILLIS D MEYER W APPELBAUM F
Citation: J. Nemunaitis et al., RETROSPECTIVE ANALYSIS OF INFECTIOUS-DISEASE IN PATIENTS WHO RECEIVEDLEUKINE VERSUS PATIENTS NOT RECEIVING A CYTOKINE WHO UNDERWENT AUTOLOGOUS BONE-MARROW TRANSPLANT (ABMT) FOR TREATMENT OF LYMPHOID CANCER, Blood, 86(10), 1995, pp. 871-871
PUVA AS ADJUVANT PRIMARY OR SALVAGE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD)
Authors: THOMPSON D SULLIVAN K SEIDEL K ERICKSON K FLOWERS M SIADAK M APPELBAUM F OLERUD J STORB R
Citation: D. Thompson et al., PUVA AS ADJUVANT PRIMARY OR SALVAGE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD), Blood, 86(10), 1995, pp. 1581-1581
G-CSF STIMULATED DONOR PERIPHERAL-BLOOD INFUSION(S) AS IMMUNOTHERAPY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES RELAPSING AFTER ALLOGENEIC TRANSPLANTATION
Authors: SULLIVAN KM MARTIN P BUCKNER CD BEACH K HIGANO T RADICH J CLIFT R BENSINGER W DEEG HJ CHAUNCEY T ROWLEY S STORB R APPELBAUM F
Citation: Km. Sullivan et al., G-CSF STIMULATED DONOR PERIPHERAL-BLOOD INFUSION(S) AS IMMUNOTHERAPY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES RELAPSING AFTER ALLOGENEIC TRANSPLANTATION, Blood, 86(10), 1995, pp. 2242-2242
PERIPHERAL-BLOOD STEM-CELLS (PBSCS) COLLECTED AFTER RECOMBINANT GRANULOCYTE-COLONY-STIMULATING FACTOR (RHG-CSF) - AN ANALYSIS OF FACTORS CORRELATING WITH THE TEMPO OF ENGRAFTMENT AFTER TRANSPLANTATION
Authors: BENSINGER WI LONGIN K APPELBAUM F ROWLEY S WEAVER C LILLEBY K GOOLEY T LYNCH M HIGANO T KLARNET J CHAUNCEY T STORB R BUCKNER CD
Citation: Wi. Bensinger et al., PERIPHERAL-BLOOD STEM-CELLS (PBSCS) COLLECTED AFTER RECOMBINANT GRANULOCYTE-COLONY-STIMULATING FACTOR (RHG-CSF) - AN ANALYSIS OF FACTORS CORRELATING WITH THE TEMPO OF ENGRAFTMENT AFTER TRANSPLANTATION, British Journal of Haematology, 87(4), 1994, pp. 825-831
FK506 IN COMBINATION WITH METHOTREXATE (MTX) FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER MARROW TRANSPLANTATION FROM PHENOTYPICALLY HLA-IDENTICAL UNRELATED DONORS
Authors: NASH RA MCSWEENEY PA STORB R GOOLEY T FURLONG T APPELBAUM F DEEG HJ DONEY K MARTIN P SULLIVAN K WITHERSPOON R ZAGER RA HANSEN JA ANASETTI C
Citation: Ra. Nash et al., FK506 IN COMBINATION WITH METHOTREXATE (MTX) FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER MARROW TRANSPLANTATION FROM PHENOTYPICALLY HLA-IDENTICAL UNRELATED DONORS, Blood, 84(10), 1994, pp. 10000394-10000394
BARRIERS TO BONE-MARROW TRANSPLANTATION FOR SICKLE-CELL-ANEMIA
Authors: WALTERS MC PATIENCE M LEISENRING W SANDERS JE MATTHEWS DC APPELBAUM F STORB R SULLIVAN KM
Citation: Mc. Walters et al., BARRIERS TO BONE-MARROW TRANSPLANTATION FOR SICKLE-CELL-ANEMIA, Blood, 84(10), 1994, pp. 10000411-10000411
LONG-TERM FOLLOW-UP OF A RANDOMIZED TRIAL OF GRAFT-VERSUS-HOST DISEASE PREVENTION BY METHOTREXATE CYCLOSPORINE VERSUS METHOTREXATE ALONE INPATIENTS GIVEN MARROW GRAFTS FOR SEVERE APLASTIC-ANEMIA/
Authors: STORB R LEISENRING W DEEG HJ ANASETTI C APPELBAUM F BENSINGER W BUCKNER CD CLIFT R DONEY K HANSEN J MARTIN P SANDERS J STEWART P SULLIVAN K THOMAS ED WITHERSPOON R
Citation: R. Storb et al., LONG-TERM FOLLOW-UP OF A RANDOMIZED TRIAL OF GRAFT-VERSUS-HOST DISEASE PREVENTION BY METHOTREXATE CYCLOSPORINE VERSUS METHOTREXATE ALONE INPATIENTS GIVEN MARROW GRAFTS FOR SEVERE APLASTIC-ANEMIA/, Blood, 83(9), 1994, pp. 2749-2750
PHASE-I STUDY OF TOTAL-BODY IRRADIATION WITH LIVER AND LUNG SHIELDING, BUSULFAN (BU) AND CYCLOPHOSPHAMIDE (CY) IN PREPARATION FOR MARROW TRANSPLANT FOR MULTIPLE-MYELOMA (MM)
Authors: BESINGER W TESH D APPELBAUM F CLIFT R STORB R HANSEN J BUCKNER D
Citation: W. Besinger et al., PHASE-I STUDY OF TOTAL-BODY IRRADIATION WITH LIVER AND LUNG SHIELDING, BUSULFAN (BU) AND CYCLOPHOSPHAMIDE (CY) IN PREPARATION FOR MARROW TRANSPLANT FOR MULTIPLE-MYELOMA (MM), Experimental hematology, 21(8), 1993, pp. 1110-1110
Risultati: 1-25 | 26-33